Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Depreciation & Amortization (CF) (2019 - 2022)

Historic Depreciation & Amortization (CF) for Cyclerion Therapeutics (CYCN) over the last 4 years, with Q2 2022 value amounting to $17000.0.

  • Cyclerion Therapeutics' Depreciation & Amortization (CF) fell 8300.0% to $17000.0 in Q2 2022 from the same period last year, while for Mar 2023 it was $17000.0, marking a year-over-year decrease of 9786.43%. This contributed to the annual value of $65000.0 for FY2022, which is 8622.88% down from last year.
  • Cyclerion Therapeutics' Depreciation & Amortization (CF) amounted to $17000.0 in Q2 2022, which was down 8300.0% from $48000.0 recorded in Q1 2022.
  • Cyclerion Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $800000.0 for Q2 2019, and its period low was $17000.0 during Q2 2022.
  • In the last 4 years, Cyclerion Therapeutics' Depreciation & Amortization (CF) had a median value of $562500.0 in 2019 and averaged $432000.0.
  • Per our database at Business Quant, Cyclerion Therapeutics' Depreciation & Amortization (CF) surged by 1923.81% in 2020 and then tumbled by 8985.2% in 2021.
  • Quarter analysis of 4 years shows Cyclerion Therapeutics' Depreciation & Amortization (CF) stood at $653000.0 in 2019, then dropped by 27.57% to $473000.0 in 2020, then tumbled by 89.85% to $48000.0 in 2021, then crashed by 64.58% to $17000.0 in 2022.
  • Its Depreciation & Amortization (CF) stands at $17000.0 for Q2 2022, versus $48000.0 for Q1 2022 and $48000.0 for Q4 2021.